Chapter 15: Antimicrobial Drugs

Antimicrobial Drugs and Modern Medicine

  • Definition of Antimicrobial Drugs: Therapeutic agents used to fight infections caused by various microorganisms, including bacteria, viruses, fungi, and parasites.
  • Role in Modern Medicine: Antimicrobials are considered the cornerstone of modern medicine.
  • Prevalence and Impact:
    • According to the U.S. Centers for Disease Control and Prevention (CDC), antimicrobials are among the most commonly prescribed drugs in the U.S.
    • More than 200×106200 \times 10^6 prescriptions for antibiotics are written each year.
    • Annually in the U.S., there are approximately 2.8×1062.8 \times 10^6 infections caused by antibiotic-resistant bacteria.
    • Approximately 35,00035,000 people die per year as a result of these resistant infections.

The Development and History of Antimicrobials

  • Etymology:
    • Antimicrobial: Derived from Greek anti (against), mikros (little), and bios (life). It refers to all agents acting against microbial organisms.
    • Antibiotic: Derived from Greek anti (against) and biotikos (concerning life).
  • Strict Definition of Antibiotics: Substances produced by microorganisms that act against another microorganism.
    • By this definition, synthetic drugs (e.g., sulfonamides, quinolones) and semisynthetic drugs (e.g., methicillin, amoxicillin) are not technically "antibiotics," though the term is often used broadly.
  • Categorization by Pathogen Target:
    • Antibacterial drugs: Treat bacterial infections.
    • Antiviral drugs: Target viral infections.
    • Antifungal drugs: Target fungal infections.
    • Antiparasitic drugs: Treat protozoan and helminthic (worm) infections.
  • Historical Context:
    • Before antimicrobials, routine infections like strep throat could be fatal.
    • Infections were the primary cause of war-related deaths throughout most of history.
    • Safe and effective antimicrobials were not developed until the 20th20^{\text{th}} century.
  • Key Discoveries:
    • Alexander Fleming (1928): While studying Staphylococcus aureus, he noticed a plate contaminated with mold (Penicillium species) where the bacteria were unable to grow near the mold. He determined the mold excreted a compound that inhibited bacteria, which he named penicillin.
    • Mass Production: Penicillin was mass-produced by 19401940 (onset of WWII) to combat streptococcal and staphylococcal infections among soldiers.
    • Streptomycin: Isolated from the soil bacterium Streptomyces griseus; it was the first effective treatment against tuberculosis.

Classification and Properties of Antimicrobial Drugs

  • Spectrum of Activity:
    • Broad-spectrum drugs: Effective against both Gram-negative and Gram-positive bacteria. Examples: levofloxacin and ciprofloxacin.
    • Narrow-spectrum drugs: Effective against a limited range of bacteria. Examples: bacitracin and vancomycin.
    • Clinical Preference: Narrow-spectrum drugs are generally preferred because they cause less disruption to normal microbiota. However, their use requires identifying the specific causative pathogen.
  • Mechanism of Action and Effectiveness:
    • Bacteriostatic: Prevent bacteria from growing. They typically target protein synthesis and metabolic pathways.
    • Bactericidal: Kill bacteria directly. They typically target cell walls, cell membranes, or nucleic acids.
    • Fluctuating Properties: A drug's status as bactericidal or bacteriostatic can change based on pathogen type, dose, length of regimen, pathogen load, and route of administration.
    • Drawbacks of Bactericidal Drugs: They can kill normal microbiota and may lead to a deadly spike in bacterial toxin release (e.g., LPS from Gram-negative cells).
  • Origins of Drugs:
    • Natural antibiotics: Naturally occurring antimicrobial compounds.
    • Synthetic antimicrobials: Manufactured entirely by chemical processes.
    • Semisynthetic antimicrobials: Chemical modifications of natural antibiotics (e.g., adding R groups) to enhance properties like spectrum of activity or stability.
      • Example: Ampicillin and amoxicillin are derived from Penicillin G but have a broader spectrum (targeting some Gram-negative) than the original (mostly Gram-positive).
  • Drug Generations:
    • First-generation: Result from the first round of chemical modification.
    • Later generations: Result from successive rounds of modification, typically offering expanded capabilities, increased stability, or the ability to bypass resistance mechanisms.

Drug Safety and Pharmacokinetics

  • Selective Toxicity: The ability of a drug to inhibit or kill a pathogen without harming the host.
  • Therapeutic Index: The ratio of the maximum tolerated (safe) dose to the minimum effective (therapeutic) dose.
    • Therapeutic Index=Maximum safe doseMinimum effective dose\text{Therapeutic Index} = \frac{\text{Maximum safe dose}}{\text{Minimum effective dose}}
    • A high therapeutic index indicates a safer drug, meaning it is effective at a dose well below its toxic threshold.
  • Administration Routes:
    • Oral: Easiest and preferred; drugs must be stable in stomach acid and absorbable in the intestines.
    • Parenteral (Injection/Infusion): Used when oral is not viable. Includes Intravenous (into vein), Intramuscular (into muscle), and Subcutaneous (under skin).
  • Half-Life: The time it takes for half of a dose to be eliminated or deactivated by the body, determining administration frequency.
    • Short half-life: Requires frequent dosing. Example: Penicillin V (half-life of 30 minutes30\,\text{minutes}, taken every 4 hours4\,\text{hours}).
    • Long half-life: Requires less frequent dosing. Example: Azithromycin (half-life up to 68 hours68\,\text{hours}, taken every 24 hours24\,\text{hours}).

Survey of Antibacterial Drugs

Cell Wall Synthesis Inhibitors (Usually Bactericidal)

Most target the production of peptidoglycan (composed of N-acetylmuramic acid, N-acetylglucosamine, and amino acids). Drugs interfere with transpeptidation (linking peptide chains), leading to cell lysis. These are most effective during the exponential growth phase.

  • Beta-Lactam Antimicrobials: Characterized by a four-sided beta-lactam ring. They bind to transpeptidase enzymes.
    • Penicillins: End in "-cillin." Generally safe; common side effects include rashes and GI upset. Main concerns are allergies and resistance.
      • Penicillin G: Natural; must be injected (acid-labile).
      • Penicillin V: Natural; can be taken orally.
      • Amoxicillin/Ampicillin: Semisynthetic; broader spectrum but susceptible to beta-lactamases.
      • Cloxacillin/Oxacillin/Nafcillin/Methicillin: Developed with bulky R groups to block beta-lactamases (steric hindrance).
      • MRSA/ORSA: Strains that altered transpeptidase enzymes so beta-lactams cannot bind.
    • Cephalosporins: Prefix "cef-" or "ceph-." Spans five generations. Successive generations show expanded activity against Gram-negative bacteria and decreased activity against Gram-positive. Fifth-generation (e.g., ceftaroline) can treat MRSA.
    • Carbapenems: Suffix "-penem." Very broad spectrum. Rise of Carbapenem-resistant Enterobacteriaceae (CRE) liked Klebsiella pneumoniae and E. coli is a major crisis.
    • Monobactams: Example: Aztreonam. Narrow-spectrum.
  • Non-Beta-Lactam Cell Wall Inhibitors:
    • Glycopeptides: Examples: Vancomycin and Teicoplanin. Interfere with cell wall synthesis but lack the beta-lactam ring (not susceptible to beta-lactamases). Effective against Gram-positive organisms (MRSA, C. difficile). Side effects include "red man syndrome."
    • Bacitracin: Polypeptide; effective against Gram-positive; used topically (Neosporin).
    • Isoniazid: Targets mycolic acid synthesis in acid-fast bacteria (Mycobacterium tuberculosis).
Nucleic Acid Synthesis Inhibitors (Usually Bactericidal)
  • Quinolones/Fluoroquinolones: Synthetic; contain fluorine. Target DNA replication enzymes (DNA gyrase and topoisomerases). Examples: Ciprofloxacin (Mycobacterium/Pseudomonas), Levofloxacin (walking pneumonia).
  • Rifamycins: Example: Rifampin. Binds to RNA polymerase to inhibit transcription. Broad-spectrum; used for mycobacteria. Note: Interferes with many other drugs (BCP, BP meds).
Folic Acid Synthesis Inhibitors (Usually Bacteriostatic)
  • Sulfa Drugs (Sulfonamides): Broad-spectrum. Target the metabolic pathway for folic acid production. Often used in combination (e.g., TMP/SMX - Trimethoprim-sulfamethoxazole).
Protein Synthesis Inhibitors (Usually Bacteriostatic)

Focus on prokaryotic ribosomes (70S70S).

  • Binding to 50S Subunit:
    • Macrolides: Examples: Erythromycin, Clarithromycin, Azithromycin. Broad-spectrum.
    • Lincosamides: Example: Clindamycin.
    • Phenicols: Example: Chloramphenicol. Broad-spectrum.
  • Binding to 30S Subunit:
    • Tetracyclines: Examples: Tetracycline, Doxycycline. Broad-spectrum. Side effects: photosensitivity, bone/teeth development issues (not for children under 88), C. diff risk.
    • Aminoglycosides: Suffix "-mycin" or "-micin." Examples: Neomycin (topical), Amikacin, Streptomycin, Gentamicin (IV). Narrow-spectrum (Gram-negative aerobes). Side effects: Irreversible hearing loss and nephrotoxicity.
Cell Membrane Disruptors (Usually Bactericidal)
  • Polypeptide Drugs: Examples: Polymyxin B and Colistin (Polymyxin E). Narrow-spectrum (Gram-negative). Interact with lipopolysaccharide (LPS) to destabilize the outer and plasma membranes. Narrow therapeutic index; used as a last resort for multidrug-resistant infections (Pseudomonas aeruginosa, Acinetobacter baumannii).

Antiviral and Eukaryotic Antimicrobial Drugs

  • Development Challenges: Difficult to target without collateral damage to host cells because the pathogens are either inside the host (viruses) or share eukaryotic structures (fungi/parasites).
  • Antiviral Drugs: Classified by the stage of the viral life cycle they inhibit:
    1. Attachment
    2. Penetration
    3. Uncoating
    4. Viral replication and assembly
    5. Viral release
    6. Immune response stimulation (e.g., interferons)
    • Effective only during active replication; latent viruses are hard to treat. Examples: Remdesivir (COVID-19), treatments for HIV, Herpes, Hepatitis, Influenza.
  • Antifungal Drugs:
    • Target fungal cell walls, plasma membranes (containing ergosterol), or nucleic acids.
    • Azoles/Allylamines: Inhibit enzymes building ergosterol.
    • Polyenes: Make membranes leaky (lysis). Examples: Nystatin (topical), Amphotericin B (life-threatening systemic infections).
    • Echinocandins: Inhibit beta-glucan synthesis in cell walls. Example: caspofungin acetate.
  • Antiprotozoan/Antihelminthic Drugs:
    • Antimalarials: Target Plasmodium species. Classes include Aminoquinolines (Chloroquine), Arylaminoalcohols (Quinine), Artemisinins.
    • Nonmalarial Antiprotozoans: Metronidazole (Flagyl) targets nucleic acids; effective against Toxoplasma gondii, Giardia, Trichomonas vaginalis.
    • Antihelminthics: Albendazole/Mebendazole (target microtubules); Praziquantel (paralyzes flukes and tapeworms).

Assessing Antimicrobial Sensitivity

  • Clinical Importance: Determination of susceptibility is essential for effective treatment and combatting the 23,00023,000 annual deaths related to resistance.
  • Agar Diffusion Tests:
    • Kirby-Bauer Test (Disk Diffusion): Bacterium is spread on Mueller-Hinton agar. Antibiotic-infused disks are added. A Zone of Inhibition (area of no growth) is measured in millimeters (mmmm).
    • E-test: Determines susceptibility.
  • Interpretation: Measured diameters are compared to a reference table to categorize results as:
    • Susceptible: Drug is likely effective.
    • Resistant: Drug is ineffective.
    • Intermediate: Borderline/uncertain response.

Section on Case Study and Practice Data

Clinical Case: The Case of the Slapdash Self-Medication
  • Explores how taking leftover antibiotics contributes to medical crises and the emergence of resistant strains.
Susceptibility Data Table (Example Results)
Drug NameObserved Diameter (mmmm)Resistant (≤\le)IntermediateSusceptible (≥\ge)
Ampicillin2020131314−1614-161717
Erythromycin1515131314−2214-222323
Ceftriaxone2525191920−2220-222323
Ciprofloxacin2323151516−2016-202121
  • Analysis of Data:
    • The test used was the Kirby-Bauer disk diffusion test (based on zone diameter measurements).
    • Based on these specific results:
      • The bacterium is Susceptible to Ampicillin (20≥1720 \ge 17), Ceftriaxone (25≥2325 \ge 23), and Ciprofloxacin (23≥2123 \ge 21).
      • The bacterium shows Intermediate sensitivity to Erythromycin (14<15<2214 < 15 < 22).
    • To ensure effectiveness, Erythromycin should likely be excluded from the treatment plan in favor of the "Susceptible" options.